The evolution and impact of sarcopenia in severe aplastic anaemia survivors following allogeneic haematopoietic cell transplantation.
Dandan ChenZhaohu YuanYuan GuoWeifeng LiuZixuan ChengLihua YeWenjian MoXinhua WeiPublished in: Journal of cachexia, sarcopenia and muscle (2024)
Sarcopenia persists in SAA patients from the time of transplant to the 1-year follow-up after HSCT. Both sarcopenia at baseline and at 6 months following HSCT are associated with poor clinical outcomes, especially in patients with persistent muscle mass loss up to 6 months after transplantation.
Keyphrases
- mesenchymal stem cells
- cell therapy
- bone marrow
- skeletal muscle
- end stage renal disease
- hematopoietic stem cell
- ejection fraction
- newly diagnosed
- chronic kidney disease
- stem cell transplantation
- single cell
- young adults
- low dose
- patient reported outcomes
- high dose
- acute lymphoblastic leukemia
- acute myeloid leukemia
- patient reported